Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases and is characterized by a wide range of alterations, including simple steatosis at early stages and steatohepatitis in advanced stages, in which fatty liver is accompanied by inflammation, hepatocyte ballooning, liver fibrosis, and disrupted glucose homeostasis and insulin resistance [1–3]. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.